Associated Papers
The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.
Pettersson H et al.
Frontiers in Oncology, 2023
37637067 (PubMed )
Supplement: Table_1.xlsx › Supplementary_table_1
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L et al.
Leukemia, 2022
35902731 (PubMed )
Supplement: 41375_2022_1648_MOESM1_ESM.xlsx › Genomic_data
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S et al.
Haematologica, 2021
Splicing and cancer: Challenges and opportunities.
Coltri PP et al.
Wiley Interdisciplinary Reviews. Rna, 2019
ZRSR2 mutation in a child with refractory macrocytic anemia and Down Syndrome.
Srinath M et al.
Pediatric Hematology and Oncology, 2019
Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.
Montes P et al.
Oncotarget, 2018
30651926 (PubMed )
Supplement: oncotarget-09-36929-s001.pdf
RNA splicing factors as oncoproteins and tumour suppressors.
Dvinge H et al.
Nature Reviews. Cancer, 2016
Select a paper to view details